Last reviewed · How we verify
Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure (ReBIC-1)
The ReBIC-1 trial was designed to evaluate the potential clinical risks and benefits of withdrawing furosemide use in stable, apparently euvolemic, chronic HF outpatients in a multicentric double-blinded randomized clinical trial.
Details
| Lead sponsor | Hospital de Clinicas de Porto Alegre |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 230 |
| Start date | 2015-05 |
| Completion | 2017-07 |
Conditions
- Heart Failure
Interventions
- Placebo
- Furosemide
Primary outcomes
- Feasibility of furosemide withdraw - proportion of patients maintained without diuretic during follow-up — 90 days
Proportion of patients maintained without diuretic during follow-up - Safety of furosemide withdraw - dyspnea score variation assessed by a visual analog scale — 90 days
Dyspnea score variation assessed by a visual analog scale after randomization
Countries
Brazil